Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2017 Results on Wednesday, February 21

Monday, February 12, 2018 1:00 PM UTC

Conference Call to be Held at 8:30am Eastern Time

HOPKINTON, Mass., Feb. 12, 2018 -- Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will host a conference call to discuss its results for the fourth quarter and fiscal year ended December 31, 2017 and its 2018 development outlook at 8:30am Eastern Time on Wednesday, February 21, 2018.

Conference Call Details
Date:		Wednesday, February 21, 2018
Time:		8:30am Eastern Time
US:		800-289-0517
International:		323-794-2423
Conference ID:		5789868
Webcast:		http://public.viavid.com/index.php?id=128299

About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly SB 9200) for the treatment of viral diseases, including hepatitis B virus (HBV). Spring Bank Pharmaceuticals is also developing other SMNH product candidates, including SB 11285, the company’s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes, or STING, pathway. For more information, please visit www.springbankpharm.com

Contacts

For investor inquires:
Spring Bank Pharmaceuticals, Inc.
Jonathan Freve
Chief Financial Officer
(508) 473-5993
[email protected]

LifeSci Advisors, LLC
Andrew McDonald, Ph.D.
(646) 597-6987
[email protected]

Media contact:
LifeSci Public Relations
Michael Tattory
(646) 751-4362
[email protected]

Source: Spring Bank Pharmaceuticals

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2017 Results on Wednesday, February 21

Editor's Picks

Welcome to EconoTimes